

DAFTAR PUSTAKA

1. Levine B, Kalman J, Mayer L, Fillit H. M, Packewr M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. *N. Engl. J. Med.* 1990;323, 236-241.
2. Dibbs Z, Kurrelmeyer K, Kalra D et al. Cytokines in heart failure: pathogenetic mechanisms and potential treatment. *Proc. Assoc. Am. Physicians* 1999;111, 423-428.
3. Torre-Amione G, Kapadia S, Benedict C. R, et al. Proinflammatory cytokine levels in patient with depressed left ventricular ejection fraction: a report from the studies of left ventricular dysfunction (SOLVD). *J. Am. Coll. Cardiol.* 1996;27, 1201-1206.
4. Testa M, Yeh M, Lee P, et al. Circulating levels of cytokines and their endogenous modulators in patient with mild to severe congestive heart failure due to coronary artery disease of hypertension. *J. Am. Coll. Cardiol.* 1996;28, 964-971.
5. Kubota T, McNamara D. M, Wang J. J, et al for the VEST investigators for TNF Genotype Analysis. Effects of tumor necrosis factor gene polymorphisms on patients with congestive heart failure. *Circulation* 1998;97, 2499-2501.
6. Tsutamoto T, Hisanaga T, Wada A, et al. Interleukin-6 spillover in the peripheral circulation increases with the severity of heart failure, and the high plasma level of interleukin-6 is an important prognostic predictor in patients with congestive heart failure. *J. Am. Coll. Cardiol.* 1998;31, 391-398.
7. de Vries J. E. Immunosuppressive and anti inflammatory properties of interleukin 10. *Ann. Med.* 1995;27, 537-541.
8. Nicod L. P, el Habre F, Dayer J. M, Boehringer N. Interleukin-10 decreases tumor necrosis factor α and β in alloreactions induced by human lung dendritic cells and macrophages. *Am. J. Respir. Cell Moll. Biol.* 1995;13, 83-90.
9. Silvestre J. S, Mallat Z, Tamarat R, Duriez M, Tedgui A, Levey B. I. Regulation of matrix metalloproteinase activity in ischemic tissue by interleukin-10: role in ischemia-induced angiogenesis. *Circ. Res.* 2001;89, 259-264.
10. Bolger A. P, Sharma R, vonHaehling S, et al. Effect of interleukin-10 on the production of tumor necrosis factor- α by peripheral blood mononuclear cells from patients with chronic heart failure. *Am. J. Cardiol.* 2002;90, 384-389.
11. Mallat Z, Besnard S, Duriez M, et al. Protective role of interleukin-10 in atherosclerosis. *Circ. Res.* 1999;85, e17-e24.

12. Smith D. A, Irving S. D, Sheldon J, Cole D, Kaski J. C. Serum Levels of anti-inflammatory cytokine interleukin-10 are decreased in patient with unstable angina. *Circulation* 2001;104, 746-749.
13. Pretolani, M. Interleukin-10: an anti inflammatory cytokine with therapeutic potential. *Clin. Exp. Allergy* 1999;29, 1164-1171.
14. Gullestad L, Aass H. J. G, et al. Immunomodulating therapy with intravenous immunoglobulin in patients with chronic heart failure. *Circulation* 2001;103, 220-225.
15. Yancy C. W, Jessup M, Bozkurt B, Butler J, Casey D. E, Drazner M. H, Fonarow G. C, Geraci S. A, Horwich T, Januzzi J. L, Johnson M. R, Kasper E. K, Levy W. C, Masoudi F. A, McBride P. E, McMurray J. J. V, Mitchell J. E, Peterson P. N, Riegel B, Sam F, Stevenson L. W, Tang, W. H. W, Tsai E. J, Wilkoff B. L. 2013 ACCF/AHA Guideline for the Management of Heart Failure A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *Circulation* 2013;128, e240–e327. doi:10.1161/CIR.0b013e31829e8776.
16. McMurray J. J. V, Adamopoulos S, Anker S. D, Auricchio A, Böhm M, Dickstein K, Falk V, Filippatos G, Fonseca C, Gomez-Sanchez M. A, Jaarsma T, Køber L, Lip G. Y. H, Maggioni A. P, Parkhomenko A, Pieske B. M, Popescu B. A, Rønnevik P. K, Rutten F. H, Schwitler J, Seferovic P, Stepinska J, Trindade P. T, Voors A. A, Zannad F, Zeiher A, (cpg) E.C. for P.G., Reviewers, D., 2012. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. *Eur. Heart J.* 2012;33, 1787–1847. doi:10.1093/eurheartj/ehs104.
17. Mann M. D. Management of Heart Failure Patients with Reduced Ejection Fraction in : Braunwald's Heart Disease a textbook Cardiovascular Medicine ninethedition. 2012 .
18. Beyaert R, Fiers W. Tumor necrosis factor and lymphotoxin. In: Mire-Sluis A, Thorpe R, (eds.). *Cytokines*. 2nd ed. London: Academic Press; 1999. p.335-45.
19. Shan K, Kurrelmeyer K, Seta Y, Wang F, Dibbs Z, Deswal A, et al. The role of cytokines in disease progression in heart failure. *Curr Opin Cardiol.* 1997;12 (3): 218-23.
20. Anker S, Steinborn W, Strassburg S. Cardiac cachexia. *Ann Med.* 2004; 36(7): 518-29.
21. Sharma R, Coats A. J. S, Anker S. D. The role of inflammatory mediators in chronic heart failure: cytokines, nitric oxide, and endothelin-1. *Int J Cardiol.* 2000;72 (2): 175-86.
22. Kang Y-M, Ma Y, Elks C, Zheng J. P, Yang Z. M, Francis J. Cross-talk between cytokines and renin-angiotensin in hypothalamic paraventricular

- nucleus in heart failure: role of nuclear factor- κ B. *Cardiovasc Res.* 2008; 79 (4):671-8.
23. Zhang Z. H, Wei S. G, Francis J, Felder R. B. Cardiovascular and renal sympathetic activation by blood-borne TNF- α in rat: the role of central prostaglandins. *Am J Physiol Regul Integr Comp Physiol.* 2003; 284 (4): R916-27.
 24. Francis J, Wei S. G, Weiss R. M, Felder R. B. Brain angiotensin-converting enzyme activity and autonomic regulation in heart failure. *Am J Physiol Heart Circ Physiol.* 2004; 287 (5): H2138-46.
 25. Adamopoulos S, Parissis J. T, Kremastinos D. T. A glossary of circulating cytokines in chronic heart failure. *Eur J Heart Fail.* 2001; 3 (5): 517-26.
 26. Anker S. D, von Haehling S. Inflammatory mediators in chronic heart failure: an overview. *Heart.* 2004; 90 (4): 464-70.
 27. Figueras M, Busquets S, Carbó N, Almendro V, Argiles JM, Lopez-Soriano F. J. Cancer cachexia results in an increase in TNF- α receptor gene expression in both skeletal muscle and adipose tissue. *Int J Oncol.* 2005; 27 (3): 855-60.
 28. Aderka D, Engelmann H, Wysenbeek A, Levo Y. The possible role of tumor necrosis factor (TNF) and its natural inhibitors, the soluble-TNF receptors, in autoimmune diseases. *Isr J Med Sci.* 1992; 28 (2): 126-30.
 29. Valgimigli M, Ceconi C, Malagutti P, Merli E, Soukhomovskaia O, Francolini G, et al. Tumor necrosis factor- α receptor 1 is a major predictor of mortality and new-onset heart failure in patients with acute myocardial infarction: the cytokine-activation and long-term prognosis in myocardial infarction (C-ALPHA) study. *Circulation.* 2005; 111 (7): 863-70.
 30. Levine B, Kalman J, Mayer L, Fillit H. M, Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. *N Engl J Med.* 1990;323 (4): 236-41.
 31. Behnke B. J, Delp M. D, McDonough P, Spier S. A, Poole D. C, Musch T. I. Effects of chronic heart failure on microvascular oxygen exchange dynamics in muscles of contrasting fiber type. *Cardiovasc Res.* 2004; 61 (2): 325-32.
 32. Paulus W, Kastner S, Pujadas P, Shah A. M, Drexler H, Vanderheyden M. Left ventricular contractile effects of inducible nitric oxide synthase in the human allograft. *Circulation.* 1997; 96: 3436-42.
 33. Gielen S, Adams V, Linke A, Erbs S, Mobius-Winkler S, Schubert A, et al. Exercise training in chronic heart failure: correlation between reduced local inflammation and improved oxidative capacity in the skeletal muscle. *Eur J Cardiovasc Prev Rehabil.* 2005; 12 (4): 393-400.
 34. Ferrari R. Tumor necrosis factor in CHF: a double facet cytokine. *Cardiovasc Res.* 1998; 37 (3): 554-9.

35. Anker S. D, Rauchhaus M. Heart failure as a metabolic problem. *Eur J Heart Fail.* 1999; 1 (2): 127-31.
36. Paulus W. J. How are cytokines activated in heart failure? *Eur J Heart Fail.* 1999; 1 (4): 309-12.
37. Larsen A. I, Lindal S, Aukrust P, Toft I, Aarsland T, Dickstein K. Effect of exercise training on skeletal muscle fibre characteristics in men with chronic heart failure. Correlation between skeletal muscle alterations, cytokines and exercise capacity. *Int J Cardiol.* 2002; 83 (1): 25-32.
38. Coats A, Clark A, Piepoli M, Volterrani M, Poole-Wilson PA. Symptoms and quality of life in heart failure: the muscle hypothesis. *Br Heart J.* 1994; 72 (2 Suppl): S36-39.
39. Duscha B. D, Annex B. H, Green H. J, Phippen A. M, Kraus W. E. Deconditioning fails to explain peripheral skeletal muscle alterations in men with chronic heart failure. *J Am Coll Cardiol.* 2002; 39 (7): 1170-4.
40. Batista M. L. Jr, Santos R, Cunha L. M, Mattos K, Oliveira EM, Seelaender MC, et al. Changes in the pro-inflammatory cytokine production and peritoneal macrophage function in rats with chronic heart failure. *Cytokine.* 2006; 34(5-6): 284-90.
41. Yndestad A, Kristian Damås J, Øie E, Ueland T, Gullestad L, Alkrust P. Systemic inflammation in heart failure – The whys and wherefores. *Heart Fail Rev.* 2006; 11 (1): 83-92.
42. Sasayama S, Matsumori A, Kihara Y. New insights into the pathophysiological role for cytokines in heart failure. *Cardiovasc Res.* 1999; 42 (3): 557-64.
43. Stumpf C, Lehner C, Yilmaz A, Daniel W. G, Garlichs C. D. Decrease of serum levels of the anti-inflammatory cytokine interleukin-10 in patients with advanced chronic heart failure. *Clin Sci (Lond).* 2003; 105 (1): 45-50.
44. Gullestad L, Semb A. G, Holt E, Skärdal R, Ueland T, Yndestad A. Effect of thalidomide in patients with chronic heart failure. *Am Heart J.* 2002; 144(5): 847-50.
45. Malefyt R. Interleukin-10. In: Mire-Sluis A, Thorpe R (eds.). *Cytokines.* 2nd ed. London: Academic Press; 1999. p. 151-61.
46. Anker S. D, von Haehling S. Inflammatory mediators in chronic heart failure: an overview. *Heart.* 2004; 90 (4): 464-70.
47. Moore K, Malefyt R, Coffman R, O'Garra A. Interleukin-10 and the interleukin-10 receptor. *Annu Rev Immunol.* 2001; 19 (1): 683-765.
48. Yamaoka M, Yamaguchi S, Okuyama M, Tomoike H. Anti-inflammatory cytokine profile in human heart failure: behavior of interleukin-10 in association with tumor necrosis factor-alpha. *Jpn Circ J.* 1999; 63 (12): 951-6.

49. Nozaki N, Yamaguchi S, Yamaoka M, Okuyama M, Nakamura H. Enhanced expression and shedding of tumor necrosis factor (TNF) receptors from mononuclear leukocytes in human heart failure. *J Moll Cell Cardiol.* 1998;30: 2003-12.
50. Bolger A. P, Sharma R, von Haehling S, Doehner W, Oliver B, Rauchaus M, et al. Effect of interleukin-10 on the production of tumor necrosis factor- α by peripheral blood mononuclear cells from patients with chronic heart failure. *Am J Cardiol.* 2002; 90 (4): 384-9.
51. Mallat Z, Besnard S, Duriez M, Deleuze V, Emmanuel F, Bureau MF, et al. Protective role of interleukin-10 in atherosclerosis. *Circ Res.* 1999; 85 (8): e17-24.
52. Denys A, Udalova I. A, Smith C, Williams L. M, Ciesielski C. J, Campbell J, et al. Evidence for a dual mechanism for IL-10 suppression of TNF- α production that does not involve inhibition of p38 mitogen-activated protein kinase or NF- κ B in primary human macrophages. *J Immunol.* 2002;168 (10): 4837-45.
53. Kaur K, Sharma A. K, Dhingra S, Singra P. K. Interplay of TNF- α and IL-10 in regulating oxidative stress in isolated adult cardiac myocytes. *J Mol Cell Cardiol.* 2006; 41 (6): 1023-30.
54. Yu Y, Zhang Z. H, Wei S. G, Chu Y, Weiss R. M, Heistad D. D, et al. Central gene transfer of interleukin-10 reduces hypothalamic inflammation and evidence of heart failure in rats after myocardial infarction. *Circ Res.* 2007; 101 (3):304-12.
55. De Waal Malefyt R, Abrams R. J, Bennett B, Figdor C. G, De Vries J. E. Interleukin (IL)-10 inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. *J Exp Med* 1991;174:1209-20.
56. Wang P, Wu P, Siegel M. I, Egan R. W, Billah M. M. Interleukin (IL)10 inhibits nuclear factor κ B(NF- κ B) activation in human monocytes: IL-10 and IL-4 suppress cytokine synthesis by different mechanisms. *J Biol Chem* 1995;270:9558-63.
57. De Waal Malefyt R, Haanen J, Spits H, Roncarolo M. G, Te Velde A, Figdor C, et al. Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigenic-specific human T cell proliferation by diminishing the antigenic-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression. *J Exp Med* 1991;174:915-24.
58. Dhingra S, Sharma A. K, Arora R. C, Slezak J, Singal P. K. IL-10-induced NF- κ B pathway activation and cardiomyocyte apoptosis. *Cardiovascular research* 2009;82,59-66.

59. Aukrust P, Ueland T, Lien E, Bendtzen K, Muller F, Andreassen A. K, Norday I, Aas H, Espevik T, Simonsen S, Froland S. S, Gullestad L. Cytokine network in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. *Am J Cardiol* 1999;83:376-382.
60. Kaur K, Dhingra S, Slezak J, Sharma A. K, Bajaj A, Singal P. K. Biology of TNF- α and IL-10, and their imbalance in heart failure. *Heart Fail Rev* 2009;14:113-123.
61. Dhingra S, Sharma A. K, Singla D. K, Singal P. K. p38 and ERK 1/2 MAPkinases mediate interplay of TNF-alpha and IL-10 in regulating oxidative stress and cardiac myocyte apoptosis. *Am J Physiol Heart Circ Physiol* 2007;293:H3524-H3531.
62. Kaur K, Sharma A. K, Dhingra S, Singal P. K. Interplay of TNF-alpha and IL-10 in regulating oxidative stress in isolated adult cardiac myocytes. *J Mol Cell Cardiol* 2006;41:1023-1030.
63. Gullestad L, Aukrust P. Review of trials in chronic heart failure showing broad-spectrum anti inflammatory approaches. *Am J Cardiol* 2005;95:17c-23c.
64. Feldman M. A, Combes A, Wagner D, Kadakomi T, Kubota T, Li Y. Y, McTiernan C. The Role of Tumor Necrosis Factor in the Pathophysiology of Heart Failure. *J Am Coll Cardiol* 2000;35:537-44.
65. Finkel M. S, Oddis C. V, Jacob T. D, Watkins S. C, Hattler B. G, Simmons R. L. Negative inotropic effects of cytokines on the heart mediated by nitric oxide. *Science* 1992;257:387-9.
66. Yokoyama T, Vaca L, Rossen R. D, Durante W, Hazarika P, Mann D. L. Cellular basis for the negative inotropic effects of tumor necrosis factor-alpha in the adult mammalian heart. *J Clin Invest* 1993;92:2303-12.
67. Eichenholz P. W, Eichacker P. Q, Hoffman W. D, Banks S. M, Parrillo J. E. D. R, Natanson C. Tumor necrosis factor challenges in canines: patterns of cardiovascular dysfunction. *Am J Physiol* 1992;263:H668 -75.
68. McTiernan C. F, Lemster B. H, Frye C. S, Combes A, Feldman A. M. Interleukin-1B phospholamban gene expression in cultured cardiomyocytes. *Circulation Res* 1997;81:493-503.
69. Gulick T, Chung M. K, Pieper S. J, Lange L. G, Schreiner G. F. Interleukin 1 and tumor necrosis factor inhibit cardiac myocyte beta-adrenergic responsiveness. *Proc Natl Acad Sci USA* 1989;86:6753-7.
70. Chung M. K, Gulick T. S, Rotondo R. E, Schreiner G. F, Lange L. G. Mechanism of cytokine inhibition of beta-adrenergic agonist stimulation of cyclic AMP in rat cardiac myocytes. Impairment of signal transduction. *Circ Res* 1990;67:753- 63.

71. Li Y. Y, McTiernan C. F, Feldman A. M. Proinflammatory cytokines regulate tissue inhibitors of metalloproteinases and disintegrin metalloproteinase in cardiac cells. *Cardiovasc Res* 1999;42:162–72.
72. Anker S. D, Coats A. J. S. Cardiac cachexia: a syndrome with impaired survival and immune and neuroendocrine activation. *Chest*. 1999; 115 (3): 836-47 Paulus W, Kastner S, Pujadas P, Shah A. M, Drexler H, Vanderheyden M. Left ventricular contractile effects of inducible nitric oxide synthase in the human allograft. *Circulation*. 1997; 96: 3436-42.
73. Stromberg A, Martensson J. Gender Differences in patients with heart failure. *European Journal of Cardiovascular Nursing* 2 2003;7-18.
74. Ho KK, Anderson KM, Kannel WB, Grossman W, Levy D. Survival after the onset of congestive cardiac failure in Framingham Heart study subjects. *Circulation* 1993;88:107 –15.
75. Kosar F, Ozguntekin G, Ozerol I, Varol E. Relationship between cytokines and tumour markers in patients with chronic heart failure. *The European Journal of Heart Failure* 8 2006;270 – 274.
76. Wang Y, Zhou Y, Meng L, Lu X, Ou N, Li X. Inflammatory Mediators in Chinese Patients With Congestive Heart Failure. *Journal of Clinical Pharmacology*, 2009;49:591-599.

